Previous studies have shown an increase in obesity prevalence in the inflammatory bowel disease (IBD) population. The popularity of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) has increased in recent years due to their effectiveness in weight management. In this comprehensive review, we evaluate the efficacy of GLP-1 RAs in the management of obesity in patients with IBD.

This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacologic management of moderate-to-severely active Crohn's disease (CD).

Currently, there is a lack of attention and research on appendicitis in the elderly population. In light of this, this study aims to comprehensively assess the burden of appendicitis in individuals aged 60 and above based on the 2021 Global Burden of Disease data, in order to provide a basis for formulating corresponding prevention and control strategies for elderly appendicitis.

The rapid development of therapies for eosinophilic esophagitis (EoE), particularly involving biologics and small molecules, has prompted questions about their roles within current treatment algorithms. We aimed to examine the relative efficacy of novel biologics, small molecules and topical steroids by evaluating clinical, endoscopic, and histological improvements.

To compare postoperative dysphagia and anti-reflux efficacy between laparoscopic floppy Nissen fundoplication with V-flap suturing (LNF-V) and conventional laparoscopic Nissen fundoplication (LNF).

Inflammatory bowel disease (IBD)is associated with extraintestinal manifestations, notably venous thromboembolism (VTE), a major cause of morbidity and mortality. Patients with IBD have a 2- to 4-fold increased risk of VTE compared to the general population. Large-scale studies examining associations between VTE and adverse outcomes in hospitalized IBD patients are limited. This study aimed to investigate associations between VTE and mortality (in-hospital and overall) in hospitalized patients with IBD.

The fecal immunochemical test (FIT) is a diagnostic modality for colorectal cancer (CRC) screening, with the US Multisociety Task Force setting an 80% adherence benchmark for follow-up colonoscopy (FUC). Guidelines recommend that FITs be performed only in the context of CRC screening.

To investigate the correlation between the occurrence of pancreatic steatosis, hepatic steatosis, and cholecystectomy, as well as the associated biochemical parameters.

Functional gastrointestinal disorders present diagnostic and therapeutic challenges, and there is a strong need for molecular markers that enable early health insights and intervention. Herein, we present an approach to assess the gut microbiome with stool-based gut metatranscriptome data from a large adult human population (n = 80,570), using irritable bowel syndrome as an example that features both an abnormal gut microbiome and a spectrum of distinct conditions.

Sarcopenia, characterized by the progressive loss of skeletal muscle mass and function, represents a significant yet underrecognized extraintestinal manifestation of inflammatory bowel disease (IBD). Imaging techniques such as dual-energy X-ray absorptiometry (DXA), computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, combined with functional performance tests, offer promising strategies for early diagnosis. However, elucidating the molecular drivers of muscle wasting remains crucial. In IBD, chronic systemic inflammation, gut microbiota dysbiosis, and malnutrition synergistically disrupt muscle homeostasis by activating catabolic pathways and suppressing anabolic signals. Key molecular mechanisms involve NF-κB and JAK/STAT3 activation, inhibition of the IGF-1/mTOR axis, and alterations in microbiota-derived metabolites. Emerging evidence supports the existence of a gut-muscle axis, mediating the systemic effects of intestinal dysbiosis on skeletal muscle integrity. This review provides a comprehensive analysis of the molecular drivers of IBD-associated sarcopenia and explores potential therapeutic interventions targeting the gut-muscle interplay to improve clinical outcomes.

High rates of migration and invasiveness are crucial factors contributing to the elevated mortality associated with liver cancer. Peptidyl-prolyl isomerase A (PPIA) has emerged as a key player in the progression of various human cancers, although its specific role in the advancement of liver cancer has not been fully elucidated. Previous research revealed that PPIA dictated nuclear factor E2-related factor 2 (Nrf2) stability to promote cancer progression. To clarify this by exploring the biological effects of PPIA and Nrf2 in liver cancer.